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Abstract 
Solitary fibrous tumor is a rare tumor type
and has an unpredictable course. Local recur-
rence rate varies between 9 and 19%, and rate
of metastatic involvement between 0 and 36 %.
It is characterized by a typical architecture and
immuno-histochemistry  tests.  The  most
important  prognostic  factor  is  the  complete
resection  of  primary  tumor.  Treatment  of
recurrences is not clearly established. If a soli-
tary fibrous tumor is too advanced to allow sur-
gical resection, radiotherapy and chemothera-
py may be used. The most often used drugs are
doxorubicine and\or ifosfamide. We report the
case of man with metastatic solitary fibrous
tumor treated with trabectedin, administered
at a dose of 1.5 mg/m² every 3 weeks. After 3
cycles, metastases had significantly decreased.
Recurrence of the disease was demonstrated 8
months after the start of trabectedin. This case
shows that trabectedin is a possible treatment
option. 
Introduction
Solitary fibrous tumor is a rare tumor type
and has an unpredictable course. Treatment of
recurrences  is  poorly  codified.  The  surgery
remains probably the reference. In the forms
too advanced for a surgical solution, it is usual
to  use  radiotherapy  and  chemotherapy.  We
describe  a  case  report  of  a  39-year-old  man
with metastatic solitary fibrous tumor treated
with trabectedin.
Case Report
Diagnosis
On July 2007, a 39-year old man without any
relevant medical history had an assessment for
chronic cough. Chest radiography revealed a
left retro-cardiac thoracic mass. CT-scan found
a  voluminous  solid,  heterogeneous,  well-
encapsulated mass, with benign aspect, devel-
oped on lower half of left thorax. Lung biopsy
concluded on solitary fibrous tumor (SFT) of
the pleura. Surgical resection was performed
on  October  2007.  Histological  examination
confirmed the diagnosis of STF and surgical
margins appeared free. In spite that this sub-
type of mesenchymatous tumor is widely con-
sidered as benign, most cases have the poten-
tial for local recurrence even after wide surgi-
cal excision. Typically, patient received regular
follow-up examination including thoracic CT-
scan.  In  February  2008,  CT-scan  revealed  a
unique 8 mm-lesion in the left lung and three
other lesions on the right lung. Physical exam
had not revealed any significant abnormalities
associated with a good performance status. No
complaints  or  functional  limitations  were
described.  These  micronodules  were  totally
nonspecific  and  asymptomatic.  Their  exact
nature  was  uncertain.  Subsequent  CT-scan
performed in Mars 2008 showed an increase in
size and number of lung lesions, and doubtful
liver images.
Lung biopsies were performed shortly after-
wards. Pathological examination showed sev-
eral very small-sized metastatic nodes in lung
parenchyma (Figure 1). The round to spindle-
shaped  cells  had  little  cytoplasm  and  round,
large-sized  nuclei  with  relatively  thin  chro-
matin and small nucleoli. Vascular component
was  prominent  with  dilated  vessels.  Mitotic
activity  was  4  out  of  10  high-power  fields.
Tumors  cells  were  immunoreactive  and
immuno-histochemistry  testing  showed  het-
erogeneous immunoreactivity for CD34, CD99
and  bcl2  (Figure  2).  Focal  and  limited
immunoreactivity was observed for P S100 and
Cytokeratins. Less than 2% of cells expressed
the proliferation marker Ki67. These examina-
tions  confirmed  the  diagnosis  of  SFT  with
metastatic  evolution,  based  on  the  shape  of
lung micronodes and of doubtful liver images
observed on CT-scan.
Treatment
Chemotherapy has been started according
to  the  MAID  (Mesna,  Doxorubicine,
Ifosfamide, Deticene) regimen, within frame-
work of the PALSAR protocol from the FNCLCC
and the French Sarcoma Group.1 After 6 cycles
of MAID, best response was stable disease. 
In January, 2009, CT-scan showed disease
progression  on  lung  metastases,  which  had
increased  in  number  and  size.  The  biggest
metastases were located in lingula and in left
lower lobe of the lung (Figure 3). The hepatic
lesions had become more visible. A second line
of chemotherapy by trabectedin has been initi-
ated with a 24-hour infusion at the dose of 
1.5 mg/m² every 3 weeks, in a compassionnate
use program. Premedication consisted on a 30-
minute IV infusion of 20 mg of dexamethasone
before administration of trabectedin, as anti-
emetic prophylaxis and for liver protection, in
accordance  with  good  practice  recommenda-
tions.2 After 3 cycles, lung metastases had sig-
nificantly  decreased  (Figure  4).  In  addition,
liver metastases had decreased in size, partic-
ularly  at  the  segment  VI  level.  After  cycle  4
administration,  trabectedin  was  definitively
terminated due to a septic shock in the context
of a grade 4 neutropenia. Subsequent CT-scan
has been done in June 2009, i.e. 2 months after
discontinuation  of  all  chemotherapy  agents.
The  pulmonary  lesions  were  still  in  partial
remission, particularly at the level of the right
hilus (Figure 5). However, second recurrence
of the disease was demonstrated in September
of the same year, i.e. 8 months after the start
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of trabectedin and 5 months after the end of
the chemotherapy.
Discussion
Solitary fibrous tumor was first described on
1931 by P. Klemperer and C. Rabin. SFT is a
rare tumor type and often discovered in a for-
tuitous way.3 Initially observed in the pleura,
SFT  has  also  been  described  at  many  other
sites, including soft tissue of orbit, of liver, thy-
roid, breast, gastro-intestinal tract, and finally
of almost all organs.4,5 SFT can occur at all ages
with the highest incidence being between 60
and 70 years without evidence of unbalanced
sex ratio.
As  this  tumor  type  has  a  slow  growth,  it
often remains asymptomatic for a long time
and can then become very voluminous.
For pathologists, SFT is well circumscribed,
often partially encapsulated, of firm consisten-
cy, and has a pearly or yellowish-white color.6-10
It is described as a patternless architecture of
spindle-shaped  cells  mimicking  sometimes
typical sarcomas like leiomyosarcoma, or syn-
ovial sarcoma. Moreover, it is characterized by
a  hemangiopericytoma-like  architecture  con-
sisting of proliferation of medium-sized, well-
formed vessels in the thick wall and hyaline,
branching  out.  Immunohistochemically,  SFT
neoplastic  tumor  cells  show  expression  of
vimentin, CD34, CD99, bcl2, and less frequent-
ly EMA and smooth muscle actin. Focal and
limited  reactivity  for  protein  S100,  cytoker-
atins,  and  desmin  has  also  been  reported.
Histological criteria to classify a SFT as malig-
nant (indicating a risk of recurrence) include
more  than  4  mitoses  out  of  10  high-power
fields,  hypercellularity,  nuclear  atypia  and
presence of necrosis. Cytogenetic data on SFT
are sparse and not coherent.
SFT  has  an  unpredictable  course.  Local
recurrence  rates  vary  between  9  and  19  %,
metastases  rates  (intra-thoracic,  osseous,
hepatic, cutaneous) vary between 0 and 36 %.
The recurrences justify a long-term follow-up
as some recurrences have appeared very lately
(until  17  years  after  initial  complete  resec-
tion).  The  most  important  prognostic  factor
remains  the  complete  resection  of  primary
tumor. Treatment of recurrences is not clearly
established and requires discussion at multi-
disciplinary medical meetings. Surgery proba-
bly remains the standard treatment. If an SFT
is too advanced to allow surgical resection, a
parallel  with  soft  tissue  sarcomas  is  usually
drawn.  Radiotherapy  and  chemotherapy  may
be used. The most often used drugs are usual-
ly doxorubicine and\or ifosfamide. In our case,
we have shown that trabectedin may be a pos-
sible  option.  Trabectedin  has  allowed  tumor
response for 8 months. 
Trabectedin  (Yondelis®)  is  a  synthetized
molecule,  initially  extracted  from  a  marine
animal (Ecteinascidia turbinata). It binds on
the minor groove of the DNA and alkylates N2
of  guanines.  It  may  interfere  with  the  DNA
repair  machinery  and  blocks  cells  in  G2-M
phase.11,12
The  European  Commission  delivered  a
Marketing Authorization in September 2007. It
is indicated for the treatment of patients with
two types of cancers: i) Advanced soft tissue
sarcoma,  after  failure  of  anthracyclines  and
ifosfamide, or who are unable to receive these
agents. Trabectedin has been studied in one
main  study  involving  266  patients  with  pro-
gressive  advanced  or  metastatic  soft  tissue
sarcoma.13 All of the patients had been treated
previously  with  an  anthracycline  and  ifos-
famide. This study compared two different tra-
bectedin regimens: 0.58 mg/m² every week for
3 weeks out of a 4-week cycle, or 1.5 mg/m²
once every three weeks. Trabectedin was more
effective when it was given once every three
weeks. Median progression-free survival was
3.3  months  versus  2.3  months  respectively
(hazard ratio, 0.755; 95% CI, 0.574 to 0.992;
P=0.0418). Efficacy data are based mainly on
liposarcoma  and  leiomyosarcoma  patients.
Results suggest that the drug may be particu-
larly effective in patients with myxoid liposar-
coma; ii) Platinum-sensitive recurrent ovarian
cancer, in association with pegylated liposomal
doxorubicin (PLD). Trabectedin (1.1 mg/m²) in
combination  with  PLD  (30  mg/m²  every  3
weeks) was compared to PLD alone (50 mg/m²
every 4 weeks) in one main study involving
672 women whose disease had recurred after
previous treatment.14 Median progression-free
survival was 7.3 months for the combination
versus 5.8 months for PLD alone (hazard ratio,
0.79;  95%  CI,  0.65  to  0.96;  P=0.0190).  The
effect of trabectedin was more pronounced in
the women whose cancer was platinum-sensi-
tive (platinum-free interval of 6-12 months);
iii)  Others  studies  are  ongoing  in  sarcoma,
ovarian  carcinoma,  breast  carcinoma  and
melanoma.
Conclusions
Solitary fibrous tumor is a rare tumor type
and has an unpredictable course. There are no
Case Report
Figure 1. Lung biopsy; several metastatic
micronodules of SFT (HES x 10).
Figure 2. Biopsy; SFT is characterized by
spindle cells with vescisular nuclei (HES x
40). All the tumoral cells are immunoreac-
tive with CD34 (x40).
Figure  3.  Computed  tomografy  scan  on
January 2009, before trabectedin.
Figure 4. Computed tomografy  scan on
March 2009, after 3 cycles of trabectedin.
Figure 5. Computed tomografy  scan on June
2009, 2 months later the end of chemoterapy.[page 94] [Rare Tumors 2011; 3:e29]
guidelines  for  the  treatment  of  recurrences.
This  case  report  suggests  a  new  treatment
option (trabectedin) and gives hope for this
indication. Unfortunately, the absence of clini-
cal  study  and  published  observation  on  this
subject does not allow drawing of formal con-
clusion. 
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